P. Pham

Predicting Cost‐Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States

Joshua D. Brown, V. Diaby, S. Schmidt, 2020, Clinical and translational science.

Predicting Cost‐Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States

Joshua D. Brown, V. Diaby, S. Schmidt, 2019, medRxiv.

Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function

Joshua D. Brown, L. Lesko, G. Lip, 2020, JAMA network open.

Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles

Joshua D. Brown, T. Thai, Ching-Yu Wang, 2020, PharmacoEconomics.

A Pharmacoepidemiologic Approach to Evaluate Real-world Effectiveness of Hormonal Contraceptives in the Presence of Drug–drug Interactions

Joshua D. Brown, A. Goodin, A. Winterstein, 2020, Epidemiology.

Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?

Joshua D. Brown, P. Pham, 2019, BMC Cardiovascular Disorders.

Leveraging Case Narratives to Enhance Patient Age Ascertainment from Adverse Event Reports

E. Wu, Yong Ma, C. Kortepeter, 2021, Pharmaceutical Medicine.

Breaking the rules for studies using real-world observational data: The case of direct-acting anticoagulants and antiepileptic drugs.

Joshua D. Brown, G. Lip, S. Schmidt, 2020, European heart journal. Cardiovascular pharmacotherapy.